Alterations in IL-6, IL-8, GM-CSF. TNF-α, and IFN-γ Release by Peripheral Mononuclear Cells in Patients with Active Vitiligo
暂无分享,去创建一个
Chieh-Shan Wu | Meng-tse Wu | H. Yu | Huifen Li | Kee-Lung Chang | Chia-Li Yu | Ching-Shuang Wu | Ching‐Shuang Wu | Kee‐Lung Chang | Meng‐tse Wu | H‐S. Yu
[1] G. Imokawa,et al. Granulocyte/macrophage colony-stimulating factor is an intrinsic keratinocyte-derived growth factor for human melanocytes in UVA-induced melanosis. , 1996, The Biochemical journal.
[2] A. Al-Fouzan,et al. STUDY OF HLA CLASS I/II AND T LYMPHOCYTE SUBSETS IN KUWAITI VITILIGO PATIENTS , 1995, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[3] L. Hegedüs,et al. High frequency of thyroid dysfunction in patients with vitiligo. , 1994, Acta dermato-venereologica.
[4] C. Yu,et al. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. , 1993, The Journal of investigative dermatology.
[5] S. Im,et al. PERIPHERAL BLOOD LYMPHOCYTE IMBALANCE IN KOREANS WITH ACTIVE VITILIGO , 1993, International journal of dermatology.
[6] R. B. Goudie,et al. Abnormal expression of MHC class II and ICAM‐1 by melanocytes in vitiligo , 1993, The Journal of pathology.
[7] J. Morelli,et al. Influence of inflammatory mediators and cytokines on human melanocyte function. , 1993, The Journal of investigative dermatology.
[8] M. Waheed,et al. In vitro assessment of 'T' lymphocyte functioning in vitiligo. Support for autoimmune hypothesis concerning the disease. , 1992, Acta Dermato-Venereologica.
[9] A. Cattaneo,et al. Plasma α-melanocyte-stimulating hormone, β-endorphin, met-enkephalin, and natural killer cell activity in vitiligo , 1992 .
[10] W. Ludwig,et al. NONSEGMENTAL VITILIGO: DECREASE OF THE CD45RA+ T‐CELL SUBSET AND EVIDENCE EOR PERIPHERAL T‐CELL ACTIVATION , 1992, International journal of dermatology.
[11] T. Luger,et al. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF beta, and UVB light. , 1992, The Journal of investigative dermatology.
[12] D. Norris,et al. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. , 1990, The Journal of investigative dermatology.
[13] D. Norris,et al. Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. , 1990, The Journal of investigative dermatology.
[14] A. Fattorossi,et al. Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives. , 1990, Annals of allergy.
[15] H. Yu,et al. Depletion and Repopulation of Langerhans Cells in Nonsegmental Type Vitiligo , 1990, The Journal of dermatology.
[16] F. Fraschini,et al. T cell subpopulations in vitiligo: a chronobiologic study. , 1990, Journal of the American Academy of Dermatology.
[17] K. Tracey,et al. Peptide Regulatory Factors CACHECTIN/TUMOUR NECROSIS FACTOR , 1989, The Lancet.
[18] M. Mantovani,et al. Circadian rhythm of natural killer cell activity in vitiligo. , 1989, Journal of the American Academy of Dermatology.
[19] E. Appella,et al. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. , 1989, Science.
[20] C. Yu,et al. Alteration of mitogenic responses of mononuclear cells by anti-ds DNA antibodies resembling immune disorders in patients with systemic lupus erythematosus. , 1989, Scandinavian journal of rheumatology.
[21] C. Yu,et al. Defective helper T cell function in IgM rheumatoid factor synthesis in patients with ankylosing spondylitis. , 1989, Scandinavian journal of rheumatology.
[22] K. Manogue,et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.
[23] J. Bystryn,et al. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. , 1988, The Journal of investigative dermatology.
[24] K. Matsushima,et al. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). , 1987, Journal of immunology.
[25] E. Martz,et al. LFA-1 and other accessory molecules functioning in adhesions of T and B lymphocytes. , 1987, Human immunology.
[26] A. P. Kelly,et al. T cell profiles in vitiligo. , 1986, Journal of the American Academy of Dermatology.
[27] A. Tosti,et al. Prevalence of autoimmune atrophic gastritis in vitiligo. , 1986, Digestion.
[28] J. Lacour,et al. Vitiligo: peripheral T‐cell subset imbalance as defined by monoclonal antibodies , 1985, The British journal of dermatology.
[29] G. Trinchieri,et al. Immune interferon: a pleiotropic lymphokine with multiple effects. , 1985, Immunology today.
[30] A. Peserico,et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. , 1985, Dermatologica.
[31] G. Naughton,et al. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. , 1983, The Journal of investigative dermatology.
[32] G. Naughton,et al. Antibodies to normal human melanocytes in vitiligo , 1983, The Journal of experimental medicine.
[33] J. Nordlund,et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. , 1982, The Journal of investigative dermatology.
[34] C. Cassimos,et al. Autoimmunity and vitiligo. , 1978, Archives of dermatology.
[35] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[36] C. J. Stevenson,et al. VITILIGO, THYROID DISEASE AND AUTOIMMUNITY , 1968, The British journal of dermatology.